CD19 and acute lymphoblastic leukemia: Su et al. found that in R/R B-ALL, the efficacy of CAR-T therapy was slightly higher than that of the CD3 CD19 bispecific antibody (blinatumomab) and significantly higher than that of traditional chemotherapy 32.